Vienna biotech Cel-Sci faces delisting threat on heels of lawsuit win

Key story highlights: Cel-Sci Corp. has received a notice from the New York Stock Exchange that its stock could be delisted if it fails to meet the exchange's requirements. The Vienna biotech must submit a plan by Aug. 13 to maintain its listing — and must regain compliance by Jan. 14, 2019. The company reported shar eholder equity of less than $6 million and net losses in its five most recent fiscal years, with total market capitalization falling below $50 million. Cel-Sci Corp. said it has…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news